IRD - Opus Genetics, Inc.

QQQ $ 604.15 $ -6.69 (-1.1 %)

DIA $ 465.94 $ -3.32 (-0.71 %)

SPY $ 667.07 $ -4.86 (-0.72 %)

TLT $ 92.11 $ 0.13 (0.14 %)

GLD $ 376.35 $ 3.48 (0.93 %)

Previous Close

$ 2.01

Open

$ 2.01

Bid

$ 1.93 x 300

Ask

$ 1.97 x 387

Day's Range

$ 1.91 - $ 2.02

52 Week Range

$ 0.65 - $ 2.16

Volume

390,562

Average Volume

Market Cap

120.42M

Beta (5Y Monthly)

$ 0.73

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-31-2025	12-31-2024	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-13-2024	06-30-2024	10-Q
6	05-10-2024	03-31-2024	10-Q
7	03-08-2024	12-31-2023	10-K
8	11-13-2023	09-30-2023	10-Q
9	08-11-2023	06-30-2023	10-Q
10	05-15-2023	03-31-2023	10-Q
11	03-30-2023	12-31-2022	10-K
12	11-04-2022	09-30-2022	10-Q
13	08-12-2022	06-30-2022	10-Q
14	05-13-2022	03-31-2022	10-Q
15	03-24-2022	12-31-2021	10-K
16	11-12-2021	09-30-2021	10-Q
17	08-12-2021	06-30-2021	10-Q
18	05-07-2021	03-31-2021	10-Q
19	03-11-2021	12-31-2020	10-K
20	10-29-2020	09-30-2020	10-Q
21	08-14-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	02-21-2020	12-31-2019	10-K
24	11-06-2019	09-30-2019	10-Q
25	08-07-2019	06-30-2019	10-Q
26	05-10-2019	03-31-2019	10-Q
27	03-07-2019	12-31-2018	10-K
28	11-02-2018	09-30-2018	10-Q
29	08-03-2018	06-30-2018	10-Q
30	05-04-2018	03-31-2018	10-Q
31	03-09-2018	12-31-2017	10-K
32	11-03-2017	09-30-2017	10-Q
33	08-04-2017	06-30-2017	10-Q
34	05-03-2017	03-31-2017	10-Q
35	02-24-2017	12-31-2016	10-K
36	11-04-2016	09-30-2016	10-Q
37	08-05-2016	06-30-2016	10-Q
38	05-06-2016	03-31-2016	10-Q
39	03-14-2016	12-31-2015	10-K
40	11-02-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

this-celestica-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

This Celestica Analyst Begins Coverage On ...
10/16/2025 12:50:15

Chardan Capital Initiates Coverage On Opus...
10/16/2025 12:37:06

Chardan Capital analyst Daniil Gataulin initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Pri...

Opus Genetics Reports Results Showing Visi...
09/30/2025 11:04:08

Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inh...

Opus Genetics Announces First Patient Has ...
09/04/2025 12:14:13

Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal di...

Opus Genetics Appoints Veteran Biotech Exe...
09/02/2025 12:14:30

Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal di...

Opus Genetics Enters Agreements For Priva...
08/25/2025 21:24:06

-SEC Filing

Opus Genetics Announces FDA Clearance Of I...
08/18/2025 12:01:41

Opus Genetics Q2 EPS $(0.12) Beats $(0.20)...
08/13/2025 20:35:38

Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.20) ...

Opus Genetics Enters Strategic Partnership...
07/23/2025 12:07:22

Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH...

viatris-hits-snag-in-eye-drug-studyphase-3-plans-under-review

Viatris Hits Snag In Eye Drug Study—Phase ...
07/18/2025 18:17:12

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reasses...

HC Wainwright & Co. Reiterates Buy on Opus...
06/27/2025 11:00:53

HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price tar...

viatris-eye-drops-data-shows-promise-for-blurred-near-vision

Viatris Eye Drops Data Shows Promise For B...
06/26/2025 17:07:47

Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patie...

Market-Moving News for June 26th
06/26/2025 11:20:59

MU: 7% | Micron shares are trading higher after the company reported better-than-expected Q3 EPS and sales and issued strong Q4...

Viatris And Opus Genetics Say VEGA-3 Phase...
06/26/2025 11:02:47

Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety pr...

Viatris And Opus Genetics Report Top-Line ...
06/26/2025 11:00:40

MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Com...

Opus Genetics Nirav Jhaveri Departs As CFO...
06/25/2025 20:26:44

https://www.sec.gov/ix?doc=/Archives/edgar/data/1228627/000114036125023648/ef20051087_8k.htm

12 Health Care Stocks Moving In Friday's P...
06/20/2025 12:09:39

LUCID CAPITAL MARKETS Initiates Coverage O...
06/17/2025 15:27:30

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces P...

Trading Halt: Halt status updated at 8:25:...
06/02/2025 12:25:06

Opus Genetics; LYNX-2 Phase 3 Trial Met Pr...
06/02/2025 12:09:54

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo...